IgA Nephropathy
Advertisement
Purespring Therapeutics received $105M in Series B funding to develop gene therapies for kidney diseases, including IgAN.
Long-term results of a study of atacicept to treat IgA nephropathy (IgAN) will be presented at ASN Kidney Week.
It is important to know the risks versus benefits of a reduced-dose methylprednisolone regimen in high-risk IgAN patients.
Patients with both IgAN and C2 lesions displayed a poor clinical prognosis requiring more effective treatment strategies.
There is a need to identify prognostic biomarkers of IgA nephropathy (IgAN) that can be used in clinical practice.
Researchers developed an updated pediatric prediction tool to determine risk for IgA nephropathy (IgAN) post-biopsy.
Researchers studied the prognostic value of a new inflammatory biomarker, the systemic immune inflammation index, in IgAN.
A new project will improve medical record access and data research awareness among patients with IgA nephropathy (IgAN).
The impact of glomerular IgM deposit on the progression of IgA nephropathy (IgAN) is unclear.
NephCure has announced the first IgA Nephropathy (IgAN) Awareness Day, happening September 26, 2024.
The FDA has granted full approval to sparsentan to slow kidney function decline in adults with primary IgA nephropathy.
Information on a possible association between chronic tonsillitis and IgA nephropathy (IgAN) has been lacking.
Prevalence of IgA nephropathy (IgAN) and a summary of treatment patterns across Asian countries are lacking.
Urinary inflammatory biomarkers may be considered as alternative predictive biomarkers in patients with IgAN.
Researchers studied the LM pattern of glomerular injury and mesangial C3 staining in IgA nephropathy (IgAN).
The FDA has granted accelerated approval of Fabhalta (iptacopan) to reduce proteinuria in adults with IgA nephropathy.
The American Kidney Fund has launched the Rare Kidney Disease Action Network.
Atrasentan showed a statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN).
IgA nephropathy (IgAN) is on the cusp of a transformational change in its treatment.
Dr. Chee Kay Cheung discussed two presentations on IgA nephropathy findings from the SPARTAN and PROTECT studies.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.